Parainfluenza Virus Type 3 Vaccine Development

Human parainfluenza viruses (HPIVs) are common respiratory pathogens and a major cause of bronchiolitis, pneumonia, and croup in infants, young children, and immunocompromised adults worldwide. Belonging to the family Paramyxoviridae, HPIVs are divided into four major serotypes (HPIV1–4), among which HPIV3 is the most virulent and is associated with the highest morbidity and mortality. HPIV3 consistently exhibits the highest detection rates across all age groups, particularly among infants and children under five, where positivity rates reach 5–8%. In hospitalized children, HPIV3 infection is associated with a median hospital stay of seven days and an ICU admission rate of approximately 7.5%. In immunocompromised populations, such as hematopoietic stem cell transplant recipients, HPIV3 can cause severe and potentially fatal pneumonia.

Despite decades of research, no licensed vaccine exists for the prevention of HPIV3 infection. Multiple vaccine candidates—including live-attenuated viruses, bovine/human chimeric constructs, mRNA formulations, and prefusion-stabilized subunit proteins—have been evaluated in preclinical models and early-phase human trials. The recent success of respiratory syncytial virus (RSV) prefusion F vaccines has catalyzed parallel efforts for HPIV3, and the field is now advancing candidates that target both pathogens in combination formulations.

Immune Response and Protection

Neutralizing antibodies targeting the HN and F glycoproteins are the primary mediators of protection against HPIV3 disease. Both serum and mucosal neutralizing antibodies contribute to immunity, but their relative importance differs by compartment: nasal IgA is a strong correlate of protection against reinfection, though its durability is limited and may require multiple infections to persist. Serum neutralizing antibodies, by contrast, provide longer-term resistance to viral replication. Young infants possess maternally derived serum IgG that confers partial protection during the first months of life, but these antibodies also suppress the immunogenicity of both parenteral non-live and mucosally delivered live vaccines—a central challenge for infant immunization.

Fig. 2 HPIV3 replication cycle and neutralizing antibody targets

Vaccine Development Strategies

Live-Attenuated Vaccines

Cold-adapted cp45: The most extensively evaluated HPIV3 vaccine candidate, cp45, was derived from the JS wild-type strain by 45 serial passages at low temperature. It contains 20 point mutations (5 silent) relative to the parental strain, including three mutations in the L polymerase protein that confer the temperature-sensitive and attenuation phenotypes. Administered intranasally, cp45 has been evaluated in Phase I/II trials and induces hemagglutination-inhibiting (HAI) antibodies in seronegative children.

Bovine/human chimeric viruses (b/HPIV3): Bovine PIV3 (BPIV3) is a host-range variant closely related to HPIV3, analogous to the use of cowpox against smallpox. The HN and F proteins of BPIV3 and HPIV3 share 78.5% and 74.6% amino acid identity, respectively. Recombinant b/HPIV3 chimeric viruses—containing BPIV3 internal genes and HPIV3 HN and F genes—have been generated by reverse genetics and are attenuated yet protective against wild-type HPIV3 challenge in preclinical models. The rhPIV3-NB candidate, in which the HPIV3 N protein is replaced by its BPIV3 counterpart, is among the most promising. B/HPIV3 vectors have also been engineered to express the hMPV F protein, initiated a Phase 1 trial in HPIV3-seropositive children aged 24 to<60 months in July 2024 (NCT06546423).

Codon-pair deoptimized (CPD) vaccines: A novel attenuation strategy reported in 2024 used codon-pair deoptimization of the HPIV3 polymerase genes to generate live-attenuated candidates. These CPD viruses were immunogenic and protective in hamster models, offering a genetically stable alternative to classical cold adaptation.

mRNA Vaccines

mRNA-1653 (Moderna): The first combination mRNA vaccine evaluated clinically for HPIV3, mRNA-1653 is a bivalent LNP-formulated vaccine encoding the full-length membrane-bound fusion proteins of both hMPV and HPIV3. In a Phase 1 trial of healthy adults aged 18–49, single doses of 25–300 μg were well tolerated and significantly increased neutralizing antibody titers against both viruses; a second dose did not further enhance responses, suggesting a single-dose regimen may be sufficient. At one year post-vaccination, hMPV neutralizing titers remained above baseline, while HPIV3 titers returned to baseline. A subsequent Phase 1 trial in seropositive children aged 18–55 months (10 μg or 30 μg) confirmed safety and immunogenicity, with hMPV-A geometric mean fold rises of 2.9–6.1. Notably, the antibody response was biased toward the prefusion F conformation, suggesting that prefusion stabilization could further improve immunogenicity.

Clover SCB-1033: A trivalent RSV/hMPV/PIV3 combination protein subunit vaccine candidate initiated Phase 1 testing in older adults (60–85 years) in June 2025 and advanced to Phase 2 in January 2026, representing a multivalent approach to respiratory virus prevention.

Subunit Vaccines

Informed by the success of RSV prefusion F vaccines, prefusion-stabilized HPIV3 F subunit candidates—including OnlyEcto and preF PIV1–4 constructs—have been evaluated in preclinical models. Adjuvanted prefusion F subunit formulations are particularly suited for older adults, in whom live-attenuated vaccines are less suitable. A chimeric FHN glycoprotein subunit vaccine formulated with a combination adjuvant induced protective immunity in animal models, demonstrating the potential of recombinant protein approaches.

Fig. 3 HPIV3 vaccine development timeline and clinical pipeline